Most pharma stocks are currently trading sideways, reflecting that the market is waiting for a clear direction. Interestingly, despite these ups and downs, both FIIs and DIIs have not reduced their holdings.
This signals that institutional investors still have strong confidence in the pharma sector. Even in this sideways trend, their belief is that once a positive trigger emerges—such as USFDA approvals, robust quarterly results, or a government policy push—the sector could gain momentum quickly.
In short, pharma is in a “wait-and-watch” mode right now, but the next breakout could be powerful.
👉 For more details, click on the link below.
